Responses
Clinical/translational cancer immunotherapy
Original research
Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response
Compose a Response to This Article
Other responses
No responses have been published for this article.
